Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ATM | Q13315 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 16/20 | 0.51 |
| ▸ | APP | P05067 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5710347 | 0.86 | MAPT (0.51) | MAPTHPGDATML3MBTL1REN | |
| SCHEMBL5710536 | 0.86 | MAPT (0.51) | MAPTHPGDATML3MBTL1REN | |
| SCHEMBL6719674 | 0.83 | L3MBTL1 (0.46) | MAPTHPGDL3MBTL1RENAPP | |
| SCHEMBL3651157 | 0.82 | MAPT (0.51) | MAPTHPGDATML3MBTL1REN | |
| SCHEMBL6720004 | 0.81 | L3MBTL1 (0.42) | MAPTHPGDL3MBTL1RENAPP | |
| SCHEMBL695301 | 0.81 | L3MBTL1 (0.54) | MAPTHPGDATML3MBTL1REN | |
| SCHEMBL6717134 | 0.80 | L3MBTL1 (0.47) | MAPTHPGDL3MBTL1RENAPP | |
| SCHEMBL6717436 | 0.80 | MAPT (0.52) | MAPTHPGDATML3MBTL1REN | |
| SCHEMBL6717628 | 0.79 | SMN1; SMN2 (0.43) | MAPTHPGDL3MBTL1RENIDO1 | |
| SCHEMBL1941923 | 0.79 | IDO1 (0.53) | L3MBTL1RENIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | WARNER-LAMBERT COMPANY LLC | 2004-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040214832-A1 | Piperazine derivative renin inhibitors | REN, ACE, AGTR2 | MAPT 3937/4885HPGD 256/4885ATM 4839/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.